Almirall, S.A. (0O9B.IL)
| Previous close | 8.74 |
| Open | 8.70 |
| Bid | 8.53 x 0 |
| Ask | 8.90 x 0 |
| Day's range | 8.67 - 8.70 |
| 52-week range | 8.49 - 12.96 |
| Volume | |
| Avg. volume | 38,856 |
| Market cap | 1.595B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | 54.50 |
| EPS (TTM) | 0.16 |
| Earnings date | N/A |
| Forward dividend & yield | 0.19 (2.15%) |
| Ex-dividend date | 13 May 2022 |
| 1y target est | N/A |
- Business Wire
Almirall’s Full-Year 2022 Results
BARCELONA, Spain, February 20, 2023--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, has announced its full-year 2022 financial results today.
- Business Wire
Almirall to Participate in the 41st Annual J.P. Morgan Healthcare Conference
BARCELONA, Spain, January 04, 2023--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, USA from 9-12 January 2023.
- Business Wire
Almirall joins FACILITATE, a patient-driven Innovative Medicines Initiative (IMI) project to enable the use of clinical trial data by study participants
BARCELONA, Spain, November 28, 2022--Almirall, S.A. (ALM), a global biopharmaceutical company focused on skin health, today announced that it is participating in FACILITATE, (FrAmework for ClInicaL trIal participants’ daTA reutilization for a fully Transparent and Ethical ecosystem) a patient-driven Innovative Medicines Initiative (IMI) project aimed to create a framework for access and reutilization of clinical trial participant data for a fully compliant and ethical ecosystem. FACILITATE main
